ASXL1 and acute myeloid leukemia: IDH mutations, frequently seen in AML patients, along with 8 other AML-related mutations, were targeted by a superRCA 12-plex panel including 9 single-nucleotide mutations (IDH1 p.R132C, IDH1 p.R132H, IDH2 p.R140Q, IDH2 p.R172K, TP53 p.R248Q, PTPN11 p.A72T, DNMT3A p.S714C, DNMT3A p.R882C and BCORL1 p.Q1039*), 2 insertions (NPM1 p.W288fs and ASXL1 p.G646fs*12) and 1 deletions (BCOR p.M1641fs*50) to monitor MRD in AML patients.